October 3, 2022
IndoVac showed an efficacy rate of 92 per cent, with “generally mild” reported side effects and no reports of deaths linked to it in trials.
IndoVac showed an efficacy rate of 92 per cent, with "generally mild" reported side effects and no reports of deaths linked to it in trials.
October 3, 2022
IndoVac showed an efficacy rate of 92 per cent, with “generally mild” reported side effects and no reports of deaths linked to it in trials.